Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vietnam Medtech Fast-Tracking System In Discussion, ASEAN News Catch-Up, And 2019 Asian Diaries Dates

Executive Summary

Vietnam is the focus of this brief update to the regular Asian Medtech Associations Regulatory Networking discussions, hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).

You may also be interested in...



Vietnam Medtech Regulation: CSDT Applies In 2022 But IVD Industry Wary Of Pharma Influence

Vietnam has adopted the ASEAN Common Submission Dossier Template and updated its medtech regulation to allow more compliance time for medtech manufacturers. But the IVD industry fears too much pharma influence in file auditing.

ASEAN Updates For Malaysia, Vietnam: Asian Medtech Associations Regulatory Networking

The latest Asian Medtech Associations Regulatory Networking discussions extended to news from Malaysia, Vietnam, Singapore and ASEAN Medical Device Directive ratification, as well as the recent update from China. This series is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).

UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024

Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel